Targeted drug can ‘diminish the suffering’ of myelofibrosis

Posted on by admin

Use of the targeted agent pacritinib significantly reduced the symptoms and burden of advanced myelofibrosis in patients, says a researcher who co-led PERSIST-1, the worldwide phase 3 clinical trial that tested the therapy. Specifically, pacritinib substantially reduced severe enlargement of the spleen, a typical feature of advanced myelofibrosis, in more than 20 percent of patients and alleviated debilitating side effects in more than 46 percent.
SOURCE: Latest Science News — ScienceDaily – Read entire story here.

Related posts:

  1. Impulsivity linked to binge eating Do you get impulsive when you're upset? If so, this could be putting you at risk for binge eating. The more impulsive you are, the more likely it is you'll binge eat when experiencing negative feelings. ...
  2. Human Hendra drug, treatment not prevention In a world first in the battle against the deadly Hendra virus, volunteers are being recruited to trial a human treatment for the virus. ...
  3. ESMO Magnitude of Clinical Benefit Scale assists oncology clinicians in evaluating anti-cancer medicines ESMO, the European Society for Medical Oncology, has announced today the publication of the ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS), a tool to assist oncology clinicians in evaluating the most effective anti-cancer medicines for their patients. ...
  4. Blood pressure medications can lead to increased risk of stroke The importance of preventing hypertension is reinforced by a study showing anti-hypertension medicines can increase stroke risk by 248 percent, according to new research. ...
  5. Obesity and weight loss change splicing pattern of obesity and type 2 diabetes genes Alternative splicing of obesity and type 2 diabetes related genes may contribute to the pathophysiology of obesity, according to research from the University of Eastern Finland. Obesity leads to changes in the splicing pattern of metabolically relevant genes such as TCF7L2 and INSR, resulting in impaired insulin action. However, weight loss, induced by either obesity surgery or a very low-calorie diet, reverses these changes. The findings, presented by Dorota Kaminska, MSc, in her doctoral dissertation, increase our understanding of splicing dysregulations in obesity and can result in a new, more targeted treatment and more accurate diagnostics of metabolic disorders. ...

Related Posts